Pasello Michela, PhD
2000: Degree in Biological Sciences at the University of Ferrara, Italy.
2007: PhD in Oncology and Experimental Pathology at the University “Alma Mater Studiorum” of Bologna, Italy.
2001: National qualification to exert the profession of Biologist.
- From 2018: Biologist (permanent staff), Laboratory of Experimental Oncology, Rizzoli Orthopaedic Institute
- 2016-18: contract researcher at the Laboratory of Experimental Oncology, Rizzoli Orthopaedic Institute
- 2010-16: contract researcher at the PROMETEO Laboratory - Section Development of Biomolecular Therapies - Project Tecnopolo
- 2007-10: contract researcher at the Laboratory for Experimental Oncology of the Rizzoli Orthopaedic Institute
- 2004-06: PhD Student at the Laboratory of Oncology Research of the Rizzoli Orthopaedic Institute
- 2003: contract researcher at the Laboratory of Oncology Research of the Rizzoli Orthopaedic Institute
- 2001-02: Student Fellow at the Department of Morphology and Embriology, University of Ferrara.
- Italian: mother language
- English: fluent
- French: basic.
Principal methods of cellular biology (eukaryotic and prokaryotic cells), biomelocular biology and methods for the evaluation of drugs citotossicity. 3D colture. Recombinant DNA technology and DNA cloning. Recombinant protein production. “Antibody phage display” method.
Excellent knowledge of computer tools for PC and Mac.
Expert processing and image analysis, expert management of spreadsheets. Expert management of databases.
Tutoring of graduating students.
Since 2003, Collaborator of Research Projects funded by AIRC, the Ministry of Health (Current and Finalized Research), the Emilia-Romagna Region and the European Union.
Members of scientific associations:
- Member of Italian Association of Cell Cultures (AICC);
- Member of the Italian Society of Cancerology (SIC);
- Member of European Association for Cancer Research (EACR);
- National orders of Biologist from 28/02/2008 (order number: 059099).
Pre-clinical characterization of bone sarcoma models (cell lines, primary cultures and PDXs) with particular interest to the identification of prognostic biomarkers.
Isolation of monoclonal antibodies for clinical uses (therapeutic and/or diagnostic) by using different methods (hybridoma and screening of phagic libraries). Development of anti-CD99 antibodies for diagnostic and therapeutic options.